Using genetic testing to improve medication management and reduce adverse drug events

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of pharmacogenomic testing in managing medication regimens for patients taking drugs influenced by genetic variations. It involves a multicenter approach to assess how genetic factors can impact drug efficacy and safety. Patients who have undergone pharmacogenomic testing within the last 120 days and have a history of adverse drug events or inadequate drug efficacy will be included in the study. The goal is to identify how personalized medication management can reduce adverse drug events and hospital readmissions.

Why it matters

Who can join: the full rules

INCLUSION CRITERIA

Patients may be included in the Study if they meet all of the following inclusion criteria:

1. Male or female patients of 25 years of age or older who are able to give their written Informed Consent to participate in a Clinical Study based on voluntary agreement with a thorough explanation of the patient's participation will be provided to them.
2. Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days ("index PGx test assessment");
3. Patient was receiving at least one medication known to be associated with allelic variation at the time of the ("index PGx test assessment"), including over-the- counter medications;
4. Patient has a history of at least one TDAE over the 24-month period preceding the PGx test assessment, or has experienced inadequate efficacy from a target drug.

EXCLUSION CRITERIA

Patients will be excluded from the Study if any of the following criteria apply:

1. Patient is currently hospitalized;
2. Patient's medical and medication history is unavailable over the 120-day period preceding the PGx test assessment;
3. Patient is unable to provide an accurate history due to mental Incapacity;
4. Patient is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Study.

Where it's running

• MD@Home
  York, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Haleh Farzanmehr, MD — Gxl
• Study coordinator: Diana Messir
• Email: Diana@integritycro.com
• Phone: 239-908-0412

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using genetic testing to improve cancer prevention in older adults

  This study is testing if genetic testing can help older adults understand their risk for cancer and guide doctors in finding and treating it earlier.

  Recruiting ClinLogic LLC · Prosper, Texas · NCT03897374

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.